Replies to post #33383 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

Bomba, I don't get the short against the box strategy either. It's the same as simply selling. The only benefit I am aware of would be to avoid short term capital gains by selling outright. But that would not apply to Fidelity's position anyway, because I believe they "mark to market." The only reason to do it here would be to lock in gains and then try to buy the shares back cheaper. Not sure what their earlier cost basis is. Now that you bring it up, you're right. There really is no reason for Fidelity to have shorted their shares, unless they had large gains to lock in at some point. Surely they are lending out their shares, at least, through their brokerage arm.

[mpreorder]

I really hope I'm wrong about this. But the PR seemed to me to indicate they killed the trial because the data didn't support continuing.
IF they ever publish (highly unlikely), or even make available (also highly unlikely), this data, we'll know for sure.

I'm aware of all they had planned for HER2. This is, after all, the construct pending approval in canine osteo.

I'm not above conspiracy-speculating, so how's this:
some tute or two were shorting themselves and needed a way out, so Advaxis cans DOC, then decides to kill a trial, opening the door for the tutes to drop the sp where they can cover cheaper. But the trial actually had indications of success and Advaxis is able to sell it, banking enough to avoid further dilution till axal gets approved in the EU.

I think this would only work if Lombardo likes both the color orange and flip-flops.